Openwater's $100M Leap: Merging Silicon & Software to Revolutionize Disease Treatment

We are thrilled to announce that Openwater has successfully raised US$100,000,000 in its latest funding round, marking a pivotal moment in our journey towards revolutionizing healthcare. Founded in 2016, Openwater was built on a transformative question: Could silicon be more effective for medical treatment than drugs someday? Today, we are closer than ever to that futuristic vision. By fusing advancements in consumer electronics, semiconductor device physics, and artificial intelligence, our team is pioneering a new era where curing disease transcends borders and redefines human health on a global scale. The substantial capital raised will empower us to bolster our research and clinical development efforts, allowing us to accelerate the translation of groundbreaking technology into practical diagnostic and therapeutic solutions. With robust clinical feasibility data already in hand, our innovations promise to diagnose and treat a wide array of conditions—from aggressive cancers and mental health disorders to debilitating strokes—while also addressing challenges such as COVID/long COVID, stimulating stem cells, and rejuvenating senescent cells. The infusion of capital enables us to refine our technology, scale our clinical trials, and collaborate with leading institutions and experts in the field. Our mission is clear: to harness the power of technology to fundamentally transform healthcare diagnostics and therapeutics, just as semiconductors and software have redefined the modern world. Openwater believes that the profound act of curing disease should not be limited by geography or resources, and this funding milestone brings us one step closer to realizing a future where advanced medical treatments are accessible, effective, and truly transformative for all.